Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447902 · ClinicalTrials.gov registry record · Phase 3
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT00447902 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 11 participants.
The verdict
NCT00447902, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more than one PI. Determine pharmacokinetic data in this co-infected population and potential utility of using therapeutic drug monitoring (TDM) in improving efficacy outcomes.
Interventions
- DRUG ritonavir
- DRUG tipranavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447902
The ClinicalTrials.gov registry entry for NCT00447902 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ritonavir is the first listed.
NCT00447902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447902 about?
NCT00447902 is a clinical study titled "Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation". The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more than one PI. Determine pharmacokinetic data in this co-infected populat...
What is the current status of trial NCT00447902?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2007-03.
What interventions are being tested in trial NCT00447902?
The interventions under investigation include: ritonavir (DRUG), tipranavir (DRUG).
Who is sponsoring clinical trial NCT00447902?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.